Japanese Gynecologic Oncology Group
8
3
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
38%
3 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix
Role: collaborator
Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
Role: collaborator
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
Role: collaborator
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
Role: collaborator
Homologous Recombination Inquiry Through Ovarian Malignancy Investigations
Role: collaborator
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Role: collaborator
Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
Role: lead
Phase III Trial of Stage I Ovarian Cancer After Surgery
Role: lead
All 8 trials loaded